Evobrutinib is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the -development and functioning of various immune cells including B -lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases.